Tocimat

Quick links to important sections

Tocimat

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tocimat

Property Description
Active ingredient Fexofenadine hydrochloride
Form Oral (tablets, capsules, suspension)
Pharmacological class Second-Generation H1-Receptor Antagonist
Common use Relief from allergy symptoms
Origin Synthetic derivative (metabolite of Terfenadine)

Definition and Pharmacological Classification

Tocimat is a trade name for a medication whose active ingredient is fexofenadine hydrochloride, which is formally classified as a second-generation antihistamine and a highly selective peripheral H1-receptor antagonist. This compound is a synthetic derivative developed as the major active metabolite of terfenadine. It belongs to a pharmacological group specifically designed to counter the effects of histamine in the body. Fexofenadine is effective in providing sustained relief from allergic symptoms.

The classification as a second-generation antihistamine is significant because these compounds are clinically recognized for their unique structure, which results in minimal penetration of the central nervous system. This selective action ensures that the therapeutic effect is primarily focused on H1 receptors located peripherally on tissues, a feature that makes the medication generally non-sedating.


Composition, Forms, and General Purpose

Tocimat is a single-ingredient product composed primarily of fexofenadine hydrochloride combined with pharmaceutical excipients that formulate it for oral administration. The medication is available in several oral dosage forms, including film-coated tablets, capsules, and a liquid oral suspension, providing flexibility for diverse patient needs.

The general purpose of Tocimat is to provide relief from the common, uncomfortable symptoms associated with allergic conditions, such as itching, sneezing, and a runny nose. The drug’s core physiological action is to manage the allergic response by blocking the effects of histamine. This mechanism works targetedly to alleviate symptoms without typically causing drowsiness. By acting as an antagonist at the H1 receptors, Tocimat intercepts the chemical cascade that leads to allergy symptoms, thereby moderating the body's reaction to allergens.

Regulatory References

  1. Fexofenadine - StatPearls - NCBI Bookshelf - NIH
  2. Fexofenadine: MedlinePlus Drug Information

What side effects are possible with Tocimat?

Possible Side Effects and Safety Information

Tocimat (topiramate) is associated with a range of documented side effects, some of which are serious and require immediate attention. The most common adverse reactions reported in clinical trials include paresthesia (tingling/numbness), weight loss, anorexia, dizziness, somnolence, and difficulties with memory or concentration.

Serious and Clinically Significant Adverse Reactions

Official regulatory sources highlight the following serious risks:

  • Acute Myopia and Secondary Angle Closure Glaucoma: A potentially permanent vision-threatening condition that requires prompt discontinuation of the drug.
  • Fetal Toxicity: Use during pregnancy is associated with an increased risk of cleft lip and/or palate in the newborn.
  • Suicidal Behavior and Ideation: As with other antiepileptic drugs, there is an increased risk of suicidal thoughts or behavior.
  • Metabolic Acidosis: Decreased serum bicarbonate levels are common and may require dose adjustment or discontinuation.
  • Hyperammonemia and Encephalopathy: This serious condition has been reported, with and without the concomitant use of valproic acid.
  • Kidney Stones: The risk of nephrolithiasis is elevated, especially when used with other carbonic anhydrase inhibitors or certain dietary regimens.

Population-Specific Safety Notes

  • Pregnancy: Tocimat should be avoided during pregnancy due to the risk of fetal harm (cleft lip/palate, being small for gestational age).
  • Pediatric Patients: Decreased sweating (oligohidrosis) and increased body temperature (hyperthermia) are risks, necessitating monitoring in this population.
  • Geriatric Patients: Dosage adjustments may be necessary due to age-related changes in kidney function.

Monitoring: Baseline and periodic measurement of serum bicarbonate is recommended due to the risk of metabolic acidosis. Gradual withdrawal of the drug is necessary to minimize the potential for increased seizure frequency.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation for Fexofenadine hydrochloride (Tocimat) defines specific manifestations and required emergency actions in case of overdose.

Overdose reports are officially characterized as infrequent and containing limited information, and the maximum tolerated dose has not been established. In the event of a suspected overdose, it is mandated by regulatory labeling that individuals seek emergency medical attention or contact a Poison Control Center immediately.


Documented Manifestations and Management

In known or suspected overdose cases, the following signs and symptoms have been formally documented in regulatory reports:

  • Dizziness
  • Drowsiness
  • Dry mouth
  • Fatigue

Management of overdose is officially recommended to be symptomatic and supportive treatment. Standard measures should be considered by medical professionals to remove any unabsorbed drug. It is formally stated that haemodialysis is not effective at removing Fexofenadine hydrochloride from the blood.

Therapeutic Uses of Tocimat

What Tocimat Treats: Main Uses and Benefits

Tocimat is generally used to help with conditions characterized by episodic or fluctuating manifestations where symptoms may become intense or disruptive. The medication is considered relevant for managing symptoms related to inflammatory or irritative states in conditions such as Seasonal Allergic Rhinitis (hay fever), perennial allergies, and Chronic Idiopathic Urticaria (long-term hives). The medication is applied in addressing symptom clusters such as frequent sneezing, runny nose, nasal itching, and itchy, watery eyes, as well as widespread skin itching (pruritus).


This supportive therapeutic approach assists with managing symptoms related to inflammatory or irritative states. “This use provides support that helps ease the overall symptom burden, which may assist with maintaining functional stability.” Is commonly used in scenarios where additional management of discomfort is required, and this feature may help patients cope more steadily with symptom fluctuations that interfere with daily functioning.


Quick Fact: Relief for Key Allergic Symptoms
Tocimat is used for managing symptoms that interfere with daily functioning, primarily symptoms that create noticeable physiological strain such as nasal, ocular, and skin irritation.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Tocimat's eligibility profile is strictly defined by regulatory documents based on age, physiological status, and underlying conditions. The only absolute prohibition against use, or contraindication, is a known hypersensitivity to fexofenadine hydrochloride or any of the product’s excipients.

Adults and adolescents 12 years and older are generally eligible for use. Pediatric eligibility is restricted by age, starting at 6 months of age for specific formulations; safety has not been established for infants younger than 6 months. Older adults 65 years and older require caution in dose selection due to the possibility of age-related kidney decline.

Use is also restricted for special populations. A reduced starting dose is formally recommended for patients with decreased renal function (kidney impairment) due to the drug’s elimination pathway. Caution is also advised for patients with hepatic impairment and a history of cardiovascular disease. Furthermore, the medication is generally not recommended for use during pregnancy or lactation unless the potential benefit is determined to justify the potential risk to the fetus or infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Regulatory Interaction Profile

The interaction profile of Tocimat (Fexofenadine) is officially documented to be driven by pharmacokinetic alterations involving specific membrane transporters rather than the liver's cytochrome P450 enzyme system. Fexofenadine is a substrate for both P-gp (Permeability Glycoprotein) and OATP (Organic Anion Transporting Polypeptide) transport proteins.

Documented Exposure-Modifying Combinations

Co-administration with certain products results in significant, quantifiable changes to the drug's systemic exposure (AUC and Cmax), as noted in regulatory labeling:

  • Increased Exposure: Co-administration with the macrolide antibiotic Erythromycin or the azole antifungal Ketoconazole substantially increases Fexofenadine plasma concentration. For instance, Ketoconazole is documented to increase the Area Under the Curve (AUC) by over 160%.
  • Decreased Exposure: Products containing aluminum and magnesium hydroxides (antacids) are documented to interfere with absorption, resulting in a significant decrease in Fexofenadine exposure, necessitating a mandatory 15-minute separation of administration.

Food and Drink Interactions

Administration of Tocimat with certain fruit juices, including grapefruit, orange, and apple juice, is documented to reduce the drug’s bioavailability due to the inhibition of intestinal OATP transporters. This interaction leads to the official instruction that the medication must be taken with water only.

Population-Specific Notes

The clearance of Fexofenadine is officially documented to be decreased in subjects with renal impairment, resulting in a heightened systemic exposure, which is an important consideration in this population.

Mechanism of Action

Mechanism of Action: Tocimat

Tocimat's action is defined by targeted modulation of cell-surface receptors and subsequent signaling pathways. The drug functions primarily through two interconnected mechanistic domains to elicit specific physiological adjustments.


Selective H1 Receptor Inverse Agonism

Tocimat operates as a selective inverse agonist at the Histamine H1 receptors expressed on cells such as vascular endothelium and smooth muscle. By binding and stabilizing the receptor in its inactive conformational state, Tocimat prevents the constitutive activity and ligand-induced activation of the receptor. This interaction interrupts the initial molecular steps of the inflammation cascade, modulating signaling cascades where histamine-driven activity is present.


Downstream Inflammatory Cascade Suppression

Beyond its primary receptor-level effect, Tocimat influences downstream inflammatory signaling sequences. The modification of early molecular steps attenuates the subsequent release of pro-inflammatory mediators, including specific cytokines, from basophils and mast cells. This action results in reduced pathway signal transduction within targeted inflammatory pathways and leads to specific alterations of physiological parameters.

Dosage and Administration Information

How to Use Tocimat: Official Administration Guidelines

Tocimat, the trade name for fexofenadine hydrochloride, is a medication approved solely for oral administration and is available in forms including tablets (30 mg, 60 mg, 180 mg) and an oral suspension. The medication's usage protocol is defined by established protocols outlining the precise route, dosage, and conditions for proper intake.

Standard Dosing and Frequency

The standard adult regimen (ages 12 and older) is typically 180 mg once daily or 60 mg twice daily (every 12 hours). Pediatric patients (ages 6 to 11 years) usually follow a 30 mg twice-daily schedule. The total daily intake should not exceed the maximum prescribed dose. The timing pattern is generally daily, whether for intermittent use during seasonal allergy periods or continuous use for chronic conditions.

Administration Conditions and Adjustments

Tocimat tablets should be taken with water. Official guidelines advise against administering the medication with fruit juices, such as grapefruit, apple, or orange, because these can interfere with the drug’s absorption. Additionally, administration must be separated by at least two hours from the use of aluminum- and magnesium-containing antacids. For patients with renal impairment (reduced kidney function), instructions mandate a dose reduction, typically initiating therapy at 60 mg once daily for adults. If a dose is missed, it should be taken as soon as remembered, but users must never take two doses at once to make up for a missed one.

Recent Clinical Evidence

Tocimat: Recent Clinical Evidence

Tocimat (Fexofenadine) is an approved medication classified as a non-sedating second-generation H1 antihistamine. Clinical research, including randomized controlled trials (RCTs) and systematic reviews, primarily focuses on its use in two main areas:


Seasonal Allergic Rhinitis (Hay Fever)

Clinical evidence consistently demonstrates Tocimat's role in managing the symptoms associated with seasonal allergic rhinitis. Pooled data from multiple placebo-controlled studies have shown a statistically significant reduction in reflective total symptom scores, which include sneezing, rhinorrhea (runny nose), and ocular symptoms (itchy/watery eyes). Certain comparative studies have suggested that Tocimat has efficacy comparable to other non-sedating antihistamines like loratadine, and a favorable profile regarding its minimal tendency to cross the blood-brain barrier, which contributes to its generally non-sedating classification.


Chronic Spontaneous Urticaria (Hives)

Research also supports the use of Tocimat for chronic spontaneous urticaria (CSU), often referred to as chronic hives. Clinical trials have reported that the drug is associated with a reduction in the severity of pruritus (itching) and the appearance of wheals (hives). For patients who may not achieve adequate relief with standard doses, clinical guidelines suggest that increasing the dose (up-dosing) is an option, a practice which has been supported by findings in some comparative studies for improving symptom control.

Frequently Asked Questions (FAQ)

Common questions about Tocimat (FAQ)

Q: How is Tocimat different from other medicines that treat the same condition?

Official documentation describes Tocimat as a non-sedating, selective peripheral H1-receptor antagonist. This means the drug's selective action contributes to its minimal penetration of the central nervous system. This feature is what makes the medicine generally non-drowsy, setting its pharmacological profile apart from some older antihistamines.

Q: Are there any non-prescription items, like supplements, that are known to interact with Tocimat?

Official drug labels specifically describe that taking Tocimat with certain fruit juices (like grapefruit, apple, and orange) and antacids containing aluminum or magnesium may affect how the medicine is absorbed. Other non-prescription supplements are not detailed in the official summary of documented interactions.

Q: If I accidentally miss a dose of Tocimat, what are the general guidelines for what to do?

Official patient guidance states that if a dose is forgotten, it should be taken as soon as the user remembers. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped entirely. Official guidance states that individuals must not take two doses at once to make up for a missed one.

Q: Can Tocimat be safely used in older adults (e.g., over 65)?

Regulatory documents indicate that use in older adults is possible, often requiring caution in dose selection. This caution is advised due to the higher likelihood of age-related changes, specifically in kidney function, which may necessitate a lower dose.

Q: I'm worried about the rare side effects of Tocimat; how is 'rare' defined in the official documents?

Adverse drug reactions in regulatory documents are typically classified using standard frequency definitions. Frequency definitions are based on regulatory standards, where 'rare' typically corresponds to a frequency seen in ge 1/10,000 to < 1/1,000 users in clinical settings.

Q: How long does it usually take to notice any change after starting Tocimat?

Studies on the drug’s effects on histamine skin reactions show that the drug begins to exhibit an antihistamine effect within one hour after the dose. The maximum effect of the medication is typically observed between two and three hours after administration.

Q: Is Tocimat known to affect mood, sleep, or concentration?

Official safety data lists sleepiness or unusual drowsiness (somnolence) as a common side effect, meaning it can influence sleep patterns. Less common effects such as nervousness or insomnia are also documented in the medicine’s official product information.

Q: Does Tocimat have any warnings about its use with alcohol?

Official patient safety information often notes that combining alcohol with any medicine that has a potential side effect of dizziness or drowsiness may increase these effects. Users are encouraged to be aware of their personal reaction to the medicine.

Q: Is it common for people to get infections while taking Tocimat?

Clinical trial data lists certain infections as common side effects of Tocimat. Official product information includes viral infection (such as cold and flu) and upper respiratory tract infection as adverse events that occurred in some users.

Q: Can men using Tocimat still plan a pregnancy with their partner?

Regulatory product information from various health authorities does not indicate that Tocimat reduces fertility in men or women. This suggests that the medication is not known to impair the ability to plan a pregnancy.

Q: Is there a generic version of Tocimat available?

Yes, the active ingredient in Tocimat, fexofenadine, is available in generic form. Regulatory lists confirming generic availability, such as the FDA’s Orange Book, show that generic products have been manufactured for several years.

Q: What does the research evidence say about Tocimat's effects over many years?

Clinical evidence has examined the safety profile of the drug for up to one year of continuous dosing. In these longer-term assessments, the drug's safety profile was studied without reports of clinically significant adverse events compared to placebo.

Q: If I have a surgery coming up, does Tocimat need to be stopped beforehand?

Guidelines generally state that if the medication is taken regularly, the preferred course is to continue regular use. If there is a need to pause, the guideline is to restart post-operatively at the next scheduled dose, or when symptoms develop if taken only as needed.

Q: If Tocimat is being used for a severe condition, is it possible to eventually lower the dose or stop it?

Dosage adjustments, including stopping or lowering the dose, are determined by the need for symptom control. For its use as an antihistamine, changing the usage is a decision made based on the ongoing management of the allergic condition.

Q: Can a person drive or operate machinery safely while using Tocimat?

Regulatory documents list side effects such as dizziness and sleepiness. Because these effects could potentially impair the ability to drive or operate machinery, individuals are encouraged to know their own response to the medication before performing tasks that require full mental alertness.

Q: Is it normal to feel a little tired when first starting Tocimat?

Yes, official clinical trial data does list fatigue as a common or uncommon adverse effect of the medication. This means that feeling some tiredness when first starting Tocimat is a documented experience for some users.

Q: Are there different safety warnings for Tocimat in the US (FDA) versus Europe (EMA)?

While the FDA and EMA have different formats and regulatory documentation systems, the core warnings and safety information for the drug are based on the same clinical data. As a result, the primary precautions for use are generally consistent between the two jurisdictions.

How should Tocimat be stored and disposed of?

How to Store and Dispose of Tocimat

The storage and disposal of Tocimat (fexofenadine hydrochloride) must strictly adhere to regulatory requirements to maintain product stability and safety.


Storage Requirements

Tocimat must be kept at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be stored away from excessive heat and moisture; therefore, storage in high-humidity areas like the bathroom is prohibited. To protect the medicine's integrity, it must be stored in the original container and kept tightly closed.


Handling and Disposal

All forms of Tocimat must be kept out of the reach of children. For the oral suspension, the container must be shaken well before each use. Disposal of unused or expired medicine should be done through an authorized medicine take-back program or according to local regulations; the product must not be flushed down a toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tocimat found in:

A-Z Index: